Cover Image
市場調查報告書

纖維肌痛 : 開發平台分析

Fibromyalgia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232816
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
纖維肌痛 : 開發平台分析 Fibromyalgia - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 80 Pages
簡介

纖維肌痛會造成肌肉骨骼系統大範圍疼痛。主要的症狀有倦怠感,頭痛,下腹部疼痛等。這個疾病的原因有遺傳要素,類風濕性關節炎,狼瘡等。

本報告提供纖維肌痛治療藥的開發情形的相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

纖維肌痛概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

纖維肌痛:企業開發中的治療藥

大學/機關研究中的治療藥

纖維肌痛:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

纖維肌痛:企業開發中的產品

大學/機關研究中的產品

纖維肌痛治療藥的開發企業

  • 第一三共
  • Intellipharmaceutics International Inc.
  • Merck & Co., Inc.
  • SWITCH Biotech LLC
  • Tonix Pharmaceuticals Holding Corp.
  • Zynerba Pharmaceuticals, Inc.

纖維肌痛:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • mirogabalin besylate
  • mirtazapine ODT
  • naltrexone hydrochloride
  • Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia
  • pregabalin XR
  • Small Molecules for Fibromyalgia
  • SWT-06101
  • TD-9855
  • TNX-102
  • ZYN-001

纖維肌痛:最近的開發平台趨勢

纖維肌痛:暫停中的計劃

纖維肌痛:開發中止的產品

纖維肌痛:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8279IDB

Summary

Global Markets Direct's, 'Fibromyalgia - Pipeline Review, H2 2016', provides an overview of the Fibromyalgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibromyalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fibromyalgia
  • The report reviews pipeline therapeutics for Fibromyalgia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fibromyalgia therapeutics and enlists all their major and minor projects
  • The report assesses Fibromyalgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fibromyalgia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fibromyalgia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibromyalgia Overview
  • Therapeutics Development
    • Pipeline Products for Fibromyalgia - Overview
    • Pipeline Products for Fibromyalgia - Comparative Analysis
  • Fibromyalgia - Therapeutics under Development by Companies
  • Fibromyalgia - Therapeutics under Investigation by Universities/Institutes
  • Fibromyalgia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fibromyalgia - Products under Development by Companies
  • Fibromyalgia - Products under Investigation by Universities/Institutes
  • Fibromyalgia - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • SWITCH Biotech LLC
    • Theravance Biopharma, Inc.
    • Tonix Pharmaceuticals Holding Corp.
    • Zynerba Pharmaceuticals, Inc.
  • Fibromyalgia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (celecoxib + famciclovir) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-1069562 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-8062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXIBU-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirtazapine ODT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Fibromyalgia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SWT-06101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-9855 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibromyalgia - Dormant Projects
  • Fibromyalgia - Discontinued Products
  • Fibromyalgia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 09, 2016: Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
      • Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
      • May 02, 2016: Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
      • Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
      • Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
      • Nov 10, 2015: Tonix Pharmaceuticals Presents Additional Data on Tonmya Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting
      • Oct 01, 2015: Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting
      • Jun 17, 2015: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg
      • Jun 11, 2015: Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR
      • May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
      • May 20, 2015: Tonix Pharmaceuticals to Present Additional Data From Completed Phase 2b Study of TNX-102 SL in Fibromyalgia at EULAR
      • May 13, 2015: Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
      • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
      • Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
      • Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fibromyalgia, H2 2016
  • Number of Products under Development for Fibromyalgia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Fibromyalgia - Pipeline by Astellas Pharma Inc., H2 2016
  • Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Fibromyalgia - Pipeline by Merck & Co., Inc., H2 2016
  • Fibromyalgia - Pipeline by SWITCH Biotech LLC, H2 2016
  • Fibromyalgia - Pipeline by Theravance Biopharma, Inc., H2 2016
  • Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
  • Fibromyalgia - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Fibromyalgia - Dormant Projects, H2 2016
  • Fibromyalgia - Dormant Projects (Contd..1), H2 2016
  • Fibromyalgia - Dormant Projects (Contd..2), H2 2016
  • Fibromyalgia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Fibromyalgia, H2 2016
  • Number of Products under Development for Fibromyalgia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top